| Ytd | 5.90% | |
| 1y | 105.48% |
| Open | 22.58 | Prev Close | 22.78 | Low | 22.48 | High | 23.08 | Mkt Cap | 2.18B |
| Vol | 200.84K | Avg Vol | 1.35M | EPS | -2.38 | P/E | -9.57 | Forward P/E | -11.02 |
| Beta | 2.07 | Short Ratio | 9.79 | Inst. Own | 108.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 21.06 | 200-d Avg | 20.59 | 1yr Est | 35.77 |
IMNM News
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to
An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6,
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with
FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date b
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and bes
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc
Immunome is evolving into a multi-asset targeted oncology platform, anchored by varegacestat's stron
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to
[url="]Immunome[/url], Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-c
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on d
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on d
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company
Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation o
On Wednesday, 807 companies reached new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.